Volume 20, Number 7—July 2014
Research
Changes in Capsule and Drug Resistance of Pneumococci after Introduction of PCV7, Japan, 2010–2013
Naoko Chiba, Miyuki Morozumi, Michi Shouji, Takeaki Wajima, Satoshi Iwata, Kimiko Ubukata
, and the Invasive Pneumococcal Diseases Surveillance Study Group
, and the Invasive Pneumococcal Diseases Surveillance Study Group
Table 2
Year-to-year changes in prevalence of vaccine and nonvaccine serotypes of Streptococcus pneumoniae in children after introduction of PCV7, Japan, April 2010–March 2013*
| Disease and serotype | Isolates, no. (%) |
p value | ||
|---|---|---|---|---|
| 2010, n = 300† | 2011, n = 146‡ | 2012, n = 156§ | ||
| Meningitis | 0.006 | |||
| VT | 42 (14.0) | 17 (11.6) | 6 (3.8) | |
| NVT |
20 (6.7) |
17 (11.6) |
15 (9.6) |
|
| Sepsis and bacteremia | <0.001 | |||
| VT | 111 (37.0) | 42 (28.8) | 13 (8.3) | |
| NVT |
48 (16.0) |
39 (26.7) |
94 (60.3) |
|
| Pneumonia | <0.001 | |||
| VT | 54 (18.0) | 14 (9.6) | 3 (1.9) | |
| NVT |
8 (2.7) |
6 (4.1) |
21 (13.5) |
|
| Other | 0.147 | |||
| VT | 13 (4.3) | 7 (4.8) | 1 (0.6) | |
| NVT |
4 (1.3) |
4 (2.7) |
3 (1.9) |
|
| Total | <0.001 | |||
| VT | 220 (73.3) | 80 (54.8) | 23 (14.7) | |
| NVT | 80 (26.7) | 66 (45.2) | 133 (85.3) | |
*PCV7, 7-valent pneumoccal conjugate vaccine; VT, vaccine serotype (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F); NVT, serotypes not included
in PCV7.
†Voluntary vaccination with PCV7.
‡Implementation of Urgent Promotion of Vaccination incentive.
§Just before the introduction of 13-valent PCV.
Page created: June 17, 2014
Page updated: June 17, 2014
Page reviewed: June 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.